Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;25(7):335–339. doi: 10.1002/clc.4950250706

T‐peak to T‐end interval may be a better predictor of high‐risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin i mutation than qt dispersion

Masami Shimizu 1,✉, Hidekazu Ino 1, Kazuyasu Okeie 1, Masato Yamaguchi 1, Mitsuru Nagata 1, Kenshi Hayashi 1, Hideki Itoh 1, Taku Iwaki 1, Kotaro Oe 1, Tetsuo Konno 1, Hiroshi Mabuchi 1
PMCID: PMC6653869  PMID: 12109867

Abstract

Background: Patients with hypertrophic cardiomyopathy (HCM) associated with a deletion of lysine 183 (K183del) in the cardiac troponin I (cTnI) gene suffer sudden cardiac death at all ages. However, the correlation between QT variables and sudden cardiac death in these patients remains uncertain.

Hypothesis: We evaluated the correlation between QT variables and sudden cardiac death and/or ventricular tach‐yarrhythmia (SCD/VT) in patients with HCM associated with the cTnI mutation.

Methods: We analyzed 10 probands with HCM associated with the cTnI gene K183del and their family members. The subjects were divided into three groups: Group A (n = 7), mutation carriers with SCD/VT; Group B (n = 16), mutation carriers without SCD/VT; Group C (n = 24), no mutation carriers. QT intervals were corrected using Bazett's formula.

Results: Maximum QTc and corrected QT dispersion were significantly longer in Groups A and B than in Group C. However, there were no differences in either parameter between Groups A and B. On the contrary, the peak‐to‐end interval of T wave/QT interval in V5 (Tpe) in Group A was significantly longer than that in Groups B and C. Logistic regression analysis revealed that Tpe was a good clinical predictor for SCD/VT in patients with HCM in this study.

Conclusions: These results suggest that Tpe rather than QT dispersion may be one of the best predictors for SCD/VT in patients with HCM associated with the K183del mutation in the cTnI gene.

Keywords: hypertrophic cardiomyopathy, troponin I, QT dispersion, transmural QT dispersion

Full Text

The Full Text of this article is available as a PDF (45.0 KB).

References

  • 1. Redwood CS, Moolman‐Smook JC, Watkins H: Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999; 44:20–36 [DOI] [PubMed] [Google Scholar]
  • 2. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F: Epidemiology of hypertrophic cardiomyopathy‐related death. Revisited in a large non‐referral‐based patient population. Circulation 2000; 102:858–864 [DOI] [PubMed] [Google Scholar]
  • 3. Maron BJ, Roberts WC, Edwards JE, McAllister HA, Foley DD, Epstein SE: Sudden death in patients with hypertrophic cardiomyopathy: Characterization of 26 patients without functional limitation. Am J Cardiol 1978; 41:803–810 [DOI] [PubMed] [Google Scholar]
  • 4. Buja G, Miorelli M, Turrini P, Melacini P, Nava A: Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993; 72:973–976 [DOI] [PubMed] [Google Scholar]
  • 5. Yetman AT, Hamilton RM, Benson LN, McCrindle BW: Long‐term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 32:1943–1950 [DOI] [PubMed] [Google Scholar]
  • 6. Yi G, Elliott P, McKenna WJ, Prasad K, Sharma S, Guo XH, Camm AJ, Malik M: QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998; 82:1514–1519 [DOI] [PubMed] [Google Scholar]
  • 7. Yan GX, Antzelevitch C: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long‐QT syndrome. Circulation 1998; 98:1928–1936 [DOI] [PubMed] [Google Scholar]
  • 8. Kokado H, Shimizu M, Yoshio H, Ino H, Okeie K, Emoto Y, Matsuyama T, Yamaguchi M, Yasuda T, Fujino N, Ito H, Mabuchi H: Clinical features of hypertrophic cardiomyopathy caused by aLys183 deletion mutation in the cardiac troponin I gene. Circulation 2000; 102:663–669 [DOI] [PubMed] [Google Scholar]
  • 9. Kimura A, Harada H, Park J‐E, Nishi H, Satoh M, Takahashi M, Hiroi S, SasaokaT, Ohbuchi N, Nakamura T, Koyanagi T, HwangT‐H, Choo J‐A, Chung K‐S, Hasagawa A, Nagai R, Okazaki O, Nakamura H, Matsuzaki M, Sakamoto T, Toshima H, Koga Y, Imaizumi T, Sasazuki T: Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997; 16:379–382 [DOI] [PubMed] [Google Scholar]
  • 10. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5:874–879 [DOI] [PubMed] [Google Scholar]
  • 11. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM: QT‐interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992; 15:739–742 [DOI] [PubMed] [Google Scholar]
  • 12. Fananapazir L, Epstein ND: Genotype‐phenotype correlations inhypertrophic cardiomyopathy. Insights provided by comparisons ofkindreds with distinct and identical β‐myosin heavy chain gene mutations. Circulation 1994; 89:22–32 [DOI] [PubMed] [Google Scholar]
  • 13. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O' Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE: Mutations in the genes for cardiac troponin T and a‐tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058–1064 [DOI] [PubMed] [Google Scholar]
  • 14. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H: Sudden death due to troponin T mutations. J Am Coll Cardiol 1997; 29:549–555 [DOI] [PubMed] [Google Scholar]
  • 15. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagege A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M: Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin‐binding protein C gene. Circulation 1998; 97:2230–2236 [DOI] [PubMed] [Google Scholar]
  • 16. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE: Mutations in the gene for cardiacmyosin‐binding protein C and late‐onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248–1257 [DOI] [PubMed] [Google Scholar]
  • 17. Bevilacqua LM, Maguire CT, Seidman JG, Seidman CE, Berul CI: QT dispersion in a‐myosin heavy‐chain familial hypertrophic cardiomyopathy mice. Pediatr Res 1999; 45:643–647 [DOI] [PubMed] [Google Scholar]
  • 18. Atiga WL, Fananapazir L, McAreavey D, Calkins H, Berger RD: Temporal repolarization lability in hypertrophic cardiomyopathy caused by β‐myosin heavy‐chain gene mutations. Circulation 2000; 101:1237–1242 [DOI] [PubMed] [Google Scholar]
  • 19. Antzelevitch C, Shimizu W, Yang X, Sicouri S: Cellular basis for QT dispersion. J Electro cardiol 1998; 30(suppl): 168–175 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES